title: Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma.
abstract: Circumscribed choroidal hemangiomas are rare ophthalmic entities that cause diminution in vision due to accumulation of subretinal and/or intraretinal fluid in the macular area. Various treatment options ranging from conventional laser to photodynamic therapy have been employed to destroy the tumor and reduce the exudation; however, either the inability to penetrate through the exudative fluid or the collateral retinal damage induced by these treatment modalities make them unsuitable for lesions within the macula. We evaluated the role of intravitreal bevacizumab, a pan-vascular endothelial growth factor (VEGF) inhibitor, in reducing the sub- and intraretinal fluid in three patients with circumscribed choroidal hemangiomas. All the patients had complete resolution of the serous retinal detachment that was maintained till at least 12 months after the first injection. Intravitreal bevacizumab may be used in combination with thermal laser or photodynamic therapy in treating circumscribed choroidal hemangiomas with subretinal fluid.
authors.affiliation: Department of Vitreoretina and Uvea Services, Dr. R. P. Center for Ophthalmic Sciences, AIIMS, New Delhi, India.
authors.forename: Subrata
authors.initials: S
authors.lastname: Mandal
authors.forename: Prashant
authors.initials: P
authors.lastname: Naithani
authors.forename: Pradeep
authors.initials: P
authors.lastname: Venkatesh
authors.forename: Satpal
authors.initials: S
authors.lastname: Garg
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001826:Body Fluids / Q000187:drug effects / Q000378:metabolism; D002830:Choroid Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005139:Eyeglasses; D005451:Fluorescein Angiography; D006391:Hemangioma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D012160:Retina / Q000187:drug effects / Q000378:metabolism; D012163:Retinal Detachment / Q000188:drug therapy / Q000209:etiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab